Posted in Collaborations, Oncology
Faran S.A. and Novartis (Hellas) S.A. are pleased to announce the beginning of their collaboration in the field of therapeutic oncology. More specifically, in the context of its cooperation with Novartis, Faran undertakes the promotion and distribution in the Greek market of its formulations Novartis TYVERB (Lapatinib) and ZYKADIA (Ceritinib).
TYVERB (Lapatinib) is indicated for the treatment of metastatic breast cancer that overstates HER2, while ZYKADIA (Ceritinib) is indicated for the treatment of non-small cell lung cancer with ALK transmutation.
This collaboration will strengthen Faran’s leading position in the field of oncology among Greek companies, as Novartis is a global leader in the research, development and production of leading drugs.
As such, Faran remains faithful to its vision and values by continuing to expand its cooperation with leading pharmaceutical companies, implementing its commitment to the Greek patient and the health system, and offering renowned therapeutic proposals of high quality & therapeutic value for the treatment of serious diseases.